A cytokine storm is a severe, potentially life-threatening immune reaction in which the body floods itself with inflammatory signaling proteins called cytokines, damaging its own tissues and organs in the process. Rather than a targeted defense against infection or disease, it’s an immune system that has lost its brakes, attacking healthy tissue as aggressively as it attacks the actual threat. The term became widely known during the COVID-19 pandemic, but cytokine storms also occur in response to cancer immunotherapy, sepsis, and autoimmune conditions.
How the Feedback Loop Works
Under normal circumstances, your immune system releases cytokines as chemical messengers. They signal white blood cells to travel to a site of infection, ramp up inflammation to contain a pathogen, and then dial things back once the job is done. In a cytokine storm, that “dial it back” step never happens.
The process starts when immune cells detect signs of a pathogen or tissue damage. They release cytokines, which recruit more immune cells to the area. Those newly arrived cells release even more cytokines. Meanwhile, the inflammation itself causes cell death, which sends out additional danger signals to surrounding tissue. Those signals recruit still more immune cells, which produce still more cytokines. This creates a self-amplifying loop: inflammation causes cell death, cell death triggers more inflammation, and the cycle accelerates until it overwhelms entire organ systems. The result is system-wide, uncontrolled inflammation rather than a focused immune response.
Common Triggers
The most common trigger today is cancer immunotherapy, particularly CAR-T cell therapy and bispecific antibodies. CAR-T therapy involves engineering a patient’s own immune cells to attack cancer, but those supercharged cells can provoke massive cytokine release. In real-world data, between 56% and 72% of CAR-T patients develop some degree of cytokine release syndrome, with symptoms typically appearing within three to four days of treatment. For some blood cancers, the onset is even faster, with a median of just one day.
Severe infections are another major trigger. COVID-19 brought this into sharp focus: the rapid deterioration seen in some patients, from manageable respiratory symptoms to life-threatening organ failure in a matter of days, was driven largely by a cytokine storm rather than by the virus itself. Bacterial sepsis, influenza, and other viral infections can also set it off. Autoimmune diseases and certain genetic conditions that affect immune regulation increase the risk as well.
Genetic Factors That Raise Risk
Not everyone facing the same infection or treatment develops a cytokine storm, and genetics play a role in that variability. Research in pediatric COVID-19 patients has identified several gene variants that correlate with higher levels of key inflammatory cytokines. Variations in the ACE2 gene (the receptor the COVID virus uses to enter cells) were linked to significantly higher levels of multiple inflammatory markers, including IL-6, one of the central drivers of cytokine storms. Variants in genes related to interferon signaling, the body’s early antiviral defense system, were associated with lower levels of protective interferons and higher levels of inflammatory proteins. In practical terms, some people’s immune systems are genetically primed to produce a stronger inflammatory response and a weaker coordinated antiviral response, a combination that favors runaway inflammation.
Symptoms and Warning Signs
The hallmark symptom is a high fever, typically above 103°F (39.4°C) in adults or 104°F (40°C) in children. But fever alone doesn’t signal a cytokine storm. It becomes concerning when fever appears alongside a cluster of other symptoms:
- Cough or difficulty breathing
- Confusion or hallucinations
- Dizziness or lightheadedness
- Rapid heartbeat
- Severe fatigue
- Headaches
- Joint and muscle pain
- Loss of appetite
- Rash
- Severe nausea, vomiting, or diarrhea
These symptoms can escalate quickly. The speed of deterioration is one of the defining features. A patient can go from stable to critically ill within hours.
How It Damages Organs
The lungs are almost always the first organ hit. The flood of inflammatory proteins causes the air sacs to fill with fluid and sticky secretions, a condition known as acute respiratory distress syndrome (ARDS). The lungs essentially lose their ability to transfer oxygen into the blood, leading to respiratory failure. This pattern was strikingly consistent across COVID-19, SARS, and MERS patients.
But the damage rarely stops at the lungs. The burst of inflammatory signals can trigger widespread tiny blood clots throughout the body’s small vessels. This can lead to heart inflammation, heart failure, irregular heart rhythms, and acute coronary events. The kidneys, liver, and pancreas are all vulnerable. When multiple organs begin failing simultaneously, the condition is called multiple organ dysfunction syndrome, which is the primary cause of death in severe cases.
Another dangerous complication is disseminated intravascular coagulation, a condition where the blood’s clotting system goes haywire, forming clots throughout the body while simultaneously depleting the clotting factors needed to stop bleeding elsewhere.
How Doctors Detect It
One of the most useful blood markers is a protein called IL-6, one of the key cytokines driving the inflammatory cascade. Normal blood levels sit around 0.7 picograms per milliliter. In CAR-T therapy patients experiencing a cytokine storm, levels often exceed 1,000 pg/mL. In COVID-19 patients, levels above 80 pg/mL proved highly predictive of respiratory failure and death. When IL-6 above 80 pg/mL appeared alongside elevated C-reactive protein (a general inflammation marker) above 97 mg/L, the combination was highly accurate at identifying patients headed for severe decline. These markers allow clinicians to intervene before full-blown organ failure sets in.
Treatment Approaches
Treatment focuses on breaking the inflammatory feedback loop before it causes irreversible organ damage. Corticosteroids remain a cornerstone, broadly suppressing the immune system’s overreaction. Beyond steroids, targeted therapies aim to block specific cytokines driving the storm.
Two main approaches have been used, particularly during COVID-19. One blocks IL-6, the inflammatory protein most closely linked to severe outcomes. The other blocks a different inflammatory messenger called IL-1. Both approaches showed benefit in critically ill patients. In one study of hospitalized COVID-19 patients, 63% of those treated with the IL-1 blocker were either never intubated or successfully taken off ventilators, compared to 42% of those treated with the IL-6 blocker. However, the IL-1 group tended to be less severely ill at the start of treatment, and after adjusting for that difference, the apparent advantage was no longer statistically significant. Both treatments were used alongside corticosteroids.
The timing of treatment matters enormously. The earlier clinicians can identify the storm and intervene, the better the chances of preventing the cascade from reaching the point of multi-organ failure. This is why the blood markers described above have become so important: they provide a window for early action before the patient’s condition deteriorates visibly.